Effects of a Novel Therapeutic Diet on Liver Enzymes and Coagulating Factors in Patients With Non-Alcoholic Fatty Liver Disease: A Parallel Randomized Trial Publisher Pubmed



Kani AH^{1, 2} ; Alavian SM³ ; Esmaillzadeh A^{1, 2} ; Adibi P⁴ ; Azadbakht L^{1, 2}
Source: Nutrition Published:2014

Abstract

Objective: There are several reports regarding the role of therapeutic diets for patients with non-alcoholic fatty liver disease (NAFLD). Therefore, the aim of this study was to determine the effects of a low-calorie, low-carbohydrate soy-containing diet on lipid profiles, liver enzymes, and coagulating factors in patients with NAFLD. Method: This was a randomized parallel clinical trial involving 45 patients with NAFLD. The participants consumed three kinds of diets for 8wk. Patients were randomly assigned to consume a low-calorie diet; a low-calorie, low-carbohydrate diet; or a low-calorie, low-carbohydrate soy-containing diet. Measurements were done according to the standard method. Results: Changes in weight were not significantly different in the three groups. The low-calorie, low-carbohydrate soy-containing diet could reduce alanine aminotransferase (-15.2±12.1 versus -6.8±4.6 in the low-calorie, low-carbohydrate diet, and -6.4±4.4 IU/L in the low-calorie diet; P=0.02) and serum fibrinogen levels (-49.1±60.1 versus -12.9±8.1 and -17.4±8.4g/L, respectively; P=0.01). Reductions in aspartate aminotransferase were significantly higher in the low-calorie, low-carbohydrate soy-containing group. Changes in lipid profiles did not differ significantly between the groups. The soy-containing diet did reduce malondialdehyde more than the other diets (P=0.01). Conclusion: A low-calorie, low-carbohydrate soy-containing diet could have beneficial effects on liver enzymes, malondialdehyde, and serum fibrinogen levels in patients with NAFLD. © 2014 Elsevier Inc.